» Articles » PMID: 1280771

The Natural History of Community-acquired Hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1992 Dec 31
PMID 1280771
Citations 333
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic liver disease develops in more than half of patients with post-transfusion hepatitis C, but little is known about the natural history of community-acquired hepatitis C.

Methods: In 1985 and 1986 we identified adults with acute non-A, non-B hepatitis in four counties in the United States and followed them prospectively. We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay.

Results: Of 130 patients with non-A, non-B hepatitis, 106 (82 percent) had HCV infection, 93 were positive for anti-HCV, and 13 were positive only for HCV RNA or anti-HCVAg. Chronic hepatitis developed in 60 (62 percent) of 97 HCV-infected patients followed for 9 to 48 months, with no relation to the risk factors for infection. Ten of the 30 patients who had liver biopsies had chronic active hepatitis. In samples collected 42 to 48 months after the onset of hepatitis, HCV RNA was detected in 12 of 13 tested patients with chronic hepatitis and in all 15 tested patients with hepatitis that had resolved. Anti-HCV persisted in all but two of the initially positive patients, for a rate of antibody loss of 0.6 per 100 person-years.

Conclusions: Patients with community-acquired hepatitis C have a high rate of chronic hepatitis. HCV may be a major cause of chronic liver disease in the United States, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.

Citing Articles

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs).

Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, La Mantia C Viruses. 2025; 17(2).

PMID: 40006918 PMC: 11860415. DOI: 10.3390/v17020163.


Biomarkers in Detection of Hepatitis C Virus Infection.

Woo J, Choi Y Pathogens. 2024; 13(4).

PMID: 38668286 PMC: 11054098. DOI: 10.3390/pathogens13040331.


Opportunities for Enhanced Prevention and Control of Hepatitis C Through Improved Screening and Testing Efforts.

Cartwright E, Patel P J Infect Dis. 2023; 229(Supplement_3):S350-S356.

PMID: 37739791 PMC: 10961945. DOI: 10.1093/infdis/jiad199.


Hepatitis C Virus Micro-Elimination Plan in Southern Italy: The "HCV ICEberg" Project.

Coppola C, Kondili L, Staiano L, Cammarota S, Citarella A, Aloisio M Pathogens. 2023; 12(2).

PMID: 36839474 PMC: 9967587. DOI: 10.3390/pathogens12020195.


A retrospective study to find the prevalence of HIV, HCV and dual HIV-HCV infection in the prison inmates.

Singh G, Lata S, Swu A, Virk N, Singh J, Thakkar S J Family Med Prim Care. 2023; 11(10):6250-6254.

PMID: 36618149 PMC: 9810970. DOI: 10.4103/jfmpc.jfmpc_788_22.